Molecule.one

Warsaw, Poland Founded: 2016 • Age: 10 yrs
AI-based software for molecule drug design and synthesis is provided.
Annual revenue $239,175 Latest available
Total funding $4.6M 2 rounds
Employees - Tracked headcount
Investors 8 Known backers
Products 5 Services tracked
Competitors 11 Brand Intelligence

About Molecule.one

Molecule.one is a company based in Warsaw (Poland) founded in 2016 by Pawel Wodarczyk Pruszynski, Piotr Byrski, and Pawel Laskarzewski. Molecule.one has raised $4.63 million across 2 funding rounds from investors including Atmos Ventures, AME Cloud Ventures and Cherubic Ventures. Molecule.one offers products and services including Custom Synthesis, SpaceM1, M1 RetroScore, Data Generation & Licensing, and MariaAI. Molecule.one operates in a competitive market with competitors including Insitro, Certara, HotSpot Therapeutics, CytoReason and GRO Biosciences, among others.

  • Headquarter Warsaw, Poland
  • Founders Pawel Wodarczyk Pruszynski, Piotr Byrski, Pawel Laskarzewski
  • Sectors
    Chemicals & Materials
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Molecule One Sp. Z O.O.
Operational Areas
Chemicals & Materials → Industrial & Technical Services Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $239.18 K (USD)
    212
    as on Dec 31, 2022
  • Net Profit
    -$1.31 M (USD)
    -122
    as on Dec 31, 2022
  • EBITDA
    -$1.23 M (USD)
    -123
    as on Dec 31, 2022
  • Total Equity Funding
    $4.63 M (USD)

    in 2 rounds

  • Latest Funding Round
    $4.63 M (USD), Seed

    May 04, 2021

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Molecule.one

Molecule.one offers a comprehensive portfolio of products and services, including Custom Synthesis, SpaceM1, M1 RetroScore, Data Generation & Licensing, and MariaAI.

Product name locked
Category locked
Primary

Reliable service for synthesizing compounds tailored to client needs.

Product name locked
Category locked
Locked

Platform for accessing over 1 trillion drug-like molecules for synthesis.

Product name locked
Category locked
Locked

AI tool to predict synthetic accessibility of novel molecules.

Product name locked
Category locked
Locked

Custom dataset creation for chemistry problem-solving.

Product name locked
Category locked
Locked

Internal agent for automating molecular synthesis processes.

People of Molecule.one

Headcount 10-50
Employee Profiles 19
Employee Profiles
People
Jan Busz
Senior Software Engineer
People
Mateusz Bruno Kamiński
Senior Fullstack Engineer
People
Stanisław Jastrzębski
CTO & Chief Scientist
People
Paweł Włodarczyk-Pruszyński
Chief Innovation Officer & Founder

Unlock access to complete

Funding Insights of Molecule.one

Molecule.one has successfully raised a total of $4.63M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $4.63 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Molecule.one

Molecule.one has secured backing from 8 investors, including venture fund and angel investors. Prominent investors backing the company include Atmos Ventures, AME Cloud Ventures and Cherubic Ventures.

All
Venture Fund
Angel
Investor Description Founded Year Domain Location
-
Locked Locked Locked
AME Cloud Ventures is focused on investing in data-driven technology companies.
Locked Locked Locked
Seed-stage technology startups are invested in by Cherubic Ventures.
Locked Locked Locked
Premium access

Investor details for Molecule.one

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Molecule.one

Investments
Premium access

Investment portfolio details for Molecule.one

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Molecule.one

Premium access

Detailed financials for Molecule.one

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Molecule.One Comparisons

Molecule.one Primary company
Description
AI-based software for molecule drug design and synthesis is ...
Location
Warsaw, Poland
Founded Year
2016
Annual Revenue
$239.18 K (USD)
Net Profit
-$1.31 M (USD)
EBITDA
-$1.23 M (USD)
Employees
Not available
Premium access

Peer comparison for Molecule.one

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Molecule.one

Molecule.one operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, Certara, HotSpot Therapeutics, CytoReason and GRO Biosciences, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
An AI-enabled platform is developed for infectious disease treatment.
Locked Locked Locked
Provider of a platform for in silico drug discovery and consulting services
Locked Locked Locked
Developer of a platform for protein function analysis
Locked Locked Locked
Immune system-based drugs are discovered via biological data analytics.
Locked Locked Locked
Synthetic biology tools are developed via genetic code recoding techniques.
Locked Locked Locked
Provider of AI-based solutions for materials informatics
Premium access

Detailed competitors of Molecule.one

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Molecule.One

Premium access

Complete news archive for Molecule.one

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Molecule.one

Molecule.one was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Molecule.one is headquartered in Warsaw, Poland.

Piotr Byrski is the current CEO of Molecule.one. They have also founded this company.

Molecule.one is a funded company, having raised a total of $4.63M across 2 funding rounds to date.

Annual revenue of Molecule.one is $239.18K as on Dec 31, 2022.

Founded in 2016 and based in Warsaw, Poland, Molecule.one operates in the biotechnology sector. AI-driven software is developed to assist in molecule drug designing and synthesis. Search criteria are selected by users, after which relevant reactions are proposed, scored for viability, and assembled into complete synthesis pathways. This technology supports research and development processes in pharmaceutical applications.

Molecule.one's top competitors include Insitro, HotSpot Therapeutics and Certara.

Molecule.one offers Custom Synthesis, SpaceM1, M1 RetroScore, Data Generation & Licensing, and MariaAI.

Molecule.one has 8 investors. Key investors include Atmos Ventures, AME Cloud Ventures, Cherubic Ventures, Possible Ventures, and Firlej Kastory.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available